誘導性多功能幹細胞製造市場規模、佔有率、成長分析、按細胞類型、按工藝、按工作流程、按產品類型、按應用、按最終用戶 - 行業預測，2024-2031

誘導性多功能幹細胞製造的全球市場規模在2022年估值為12.2億美元，從2023年的13.5億美元成長到2031年的30億美元，並預計在預測期內成長（2024-預計將以2031 年複合年成長率為10.5%）。

全球誘導性多功能幹細胞(iPSC) 製造市場在再生醫學和細胞治療領域正在經歷快速成長和創新。源自成體細胞並重新編程為多功能狀態的 iPSC 為個人化治療選擇和疾病建模提供了巨大潛力。這種成長是由於人們越來越認知到 iPSC 的多種應用（從藥物發現到各種疾病的治療）。研究人員和生物技術公司正在努力開發高效的 iPSC 生產方法，在學術界、工業界和醫療保健部門之間的合作的推動下，確保可擴展性和成本效益。然而，嚴格的監管標準和道德考量在影響 iPSC 的生產方式方面發揮關鍵作用，凸顯了標準化方案和安全措施的重要性。隨著全球醫療保健格局的發展，iPSC 製造市場預計將進一步擴大，為突破性的醫學進步和治療性介入鋪平道路。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場危機與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 專利分析
• 市場生態系統
• 價值鏈分析
• 監管環境
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 競爭程度

按細胞類型分類的誘導性多功能幹細胞製造市場

• 市場概況
• 肝細胞
• 纖維母細胞
• 角質形成細胞
• 神經元
• 其他

依製程分類的誘導性多功能幹細胞製造市場

• 市場概況
• 手動 iPSC 製造流程
• 自動化 iPSC 製造流程

依工作流程誘導性多功能幹細胞製造市場

• 市場概況
• 重編程、細胞培養
• 細胞表徵/分析
• 工程
• 其他

按產品分類的誘導性多功能幹細胞製造市場

• 市場概況
• 設備/裝置
• 自動化平台
• 耗材和套件
  • 媒體
  • 套件
  • 其他
• 服務

按應用分類的誘導誘導性多功能幹細胞製造市場

• 市場概況
• 醫藥開發
• 再生醫學
• 毒性試驗
• 人體組織工程
• 其他

最終用戶誘導性多功能幹細胞製造市場

• 市場概況
• 研究/學術機構
• 生物技術和製藥公司
• 醫院/診所

按地區分類的市場規模

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Axl Bioscience Ltd.（UK）
• Cynata Therapeutics Limited（UK）
• Evotec SE（Germany）
• Fate Therapeutics, Inc.（US）
• FUJIFILM Cellular Dynamics, Inc.（US）
• Ncardia（Belgium）
• Pluricell Biotech（Spain）
• REPROCELL USA, Inc.（US）
• Sumitomo Dainippon Pharma Co., Ltd.（Japan）
• Takara Bio, Inc.（Japan）
• Thermo Fisher Scientific, Inc.（US）
• ViaCyte, Inc.（US）

Global Induced Pluripotent Stem Cells Production Market size was valued at USD 1.22 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3 billion by 2031, growing at a CAGR of 10.5% during the forecast period (2024-2031).

The global market for induced pluripotent stem cell (iPSC) manufacturing is experiencing rapid growth and innovation within the field of regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed to a pluripotent state, iPSCs offer significant potential for personalized treatment options and disease modeling. This growth is fueled by increasing awareness of iPSCs' diverse applications, spanning from drug discovery to treating various medical conditions. Efforts are underway by researchers and biotech firms to develop efficient iPSC production methods that ensure scalability and cost-effectiveness, facilitated by collaborations across academia, industry, and healthcare sectors. However, stringent regulatory standards and ethical considerations play a crucial role in shaping iPSC manufacturing practices, emphasizing the importance of standardized protocols and safety measures. As the global healthcare landscape evolves, the iPSC manufacturing market is poised for further expansion, promising avenues for groundbreaking medical advances and therapeutic interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Induced Pluripotent Stem Cells Production Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Induced Pluripotent Stem Cells Production Market Segmental Analysis

The induced pluripotent stem cells production market is segmented on the basis of cell type, process, workflow, product, application, end-use and region. Based on cell type, the market is segmented into Hepatocytes, Fibroblasts, Keratinocytes, Neurons and Others. Based on the process, the market is segmented into Manual iPSC Production Process and Automated iPSC Production Process. Based on workflow, the market is segmented into Reprogramming, Cell Culture, Cell Characterization/Analysis, Engineering, and Others. Based on product, the market is segmented into Instruments/ Devices, Automated Platforms, Consumables & Kits (Media, Kits, Others), and Services. Based on application, the market is segmented into Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, and Others. Based on end-user, the market is segmented into Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Drivers of the Global Induced Pluripotent Stem Cells Production Market

A significant driving force in the global pluripotent stem cell (iPSC) manufacturing market is the ongoing advancements in regenerative medicine. iPSCs offer substantial potential for tailoring effective therapies across various medical conditions, prompting substantial investments in research and development. This advancement propels market expansion through broadening the range of iPSC applications, offering novel treatment avenues, and drawing investments from pharmaceutical firms and healthcare institutions.

Restraints in the Global Induced Pluripotent Stem Cells Production Market

One significant obstacle in the global iPSC production market stems from ethical and regulatory hurdles. Issues surrounding the use of human-derived materials and the potential for iPSC technology misuse have led to the implementation of strict regulations in certain regions. These challenges may impede research endeavors, increase compliance costs, and generate market uncertainty, thereby affecting the pace of iPSC adoption and commercialization.

Market Trends of the Global Induced Pluripotent Stem Cells Production Market

One significant trend in the global induced pluripotent stem cell (iPSC) manufacturing market is the growing utilization of iPSCs for disease modeling, with researchers and pharmaceutical companies employing iPSC technology to generate disease-specific cell lines. This approach enables more precise and personalized modeling of a range of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular ailments. Such advancements facilitate drug discovery and development while also fostering the development of targeted and efficient therapeutic strategies, thereby influencing the trajectory of precision medicine in the future.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Patent Analysis
• Ecosystem of the Market
• Value Chain Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Induced Pluripotent Stem Cells Production Market by Cell Type

• Market Overview
• Hepatocytes
• Fibroblasts
• Keratinocytes
• Neurons
• Others

Induced Pluripotent Stem Cells Production Market by Process

• Market Overview
• Manual iPSC Production Process
• Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Market by Workflow

• Market Overview
• Reprogramming, Cell Culture
• Cell Characterization/Analysis
• Engineering
• Others

Induced Pluripotent Stem Cells Production Market by Product

• Market Overview
• Instruments/ Devices
• Automated Platforms
• Consumables & Kits
  • Media
  • Kits
  • Others
• Services

Induced Pluripotent Stem Cells Production Market by Application

• Market Overview
• Drug Development
• Regenerative Medicine
• Toxicity Testing
• Tissue Engineering
• Others

Induced Pluripotent Stem Cells Production Market by End-user

• Market Overview
• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Axl Bioscience Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics Limited (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Cellular Dynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ncardia (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluricell Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REPROCELL USA, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViaCyte, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments